Your session is about to expire
← Back to Search
EBV-specific CTLs for EBV Infection
Study Summary
This trial will test whether related donor EBV-specific CTLs can be used to treat patients with EBV infection who have had an AlloHSCT, PID, or solid organ transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are offering participation in this clinical trial?
"This trial is available at 8 medical centres, including Washington University in Saint Louis, Children's Hospital of Pennsylvania in Philadelphia and Nationwide Children's Hosptial in Columbus."
Who meets the criteria to partake in this investigation?
"This clinical trial is open to 20 participants between 1 Month and 30 years old who possess a Epstein-Barr Virus infection. Furthermore, the prospective patient requires an HLA A, B, DR match with their related donor of at least one level, as well as IgG positivity to EBV and/or a T-cell response measured by MACS® GMP PepTivator EBV Select (containing antigens such as NA-1, LMP2A and BZLF-1)."
How many participants can the trial accommodate?
"To properly conduct this medical trial, 20 participants are needed who qualify for the study's eligibility requirements. Washington University in Saint Louis, Missouri and Children's Hospital of Pennsylvania in Philadelphia, Pennsylvania are two possible locations where individuals can sign-up to join."
Is enrollment for this research study still being accepted?
"Yes, the available evidence suggests that this clinical trial is currently recruiting. The study was initially posted on July 7th 2020 and last updated September 27th 2022. 20 patients are needed across 8 medical locations to complete enrolment."
Is this research inclusive of geriatric participants?
"This clinical trial seeks to enrol participants that are above 1 Month years and younger than 30."
Has the FDA sanctioned cytotoxic t-lymphocytes for clinical use?
"The safety of cytotoxic t-lymphocytes was estimated to be a 2 since, in Phase 2 trials there is evidence suggesting it's benign albeit lacking efficacy data."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger